Author:
Cavarretta I T,Neuwirt H,Untergasser G,Moser P L,Zaki M H,Steiner H,Rumpold H,Fuchs D,Hobisch A,Nemeth J A,Culig Z
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Molecular Biology
Reference68 articles.
1. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC . (1999). Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 161: 182–187.
2. Akira S, Taga T, Kishimoto T . (1993). Interleukin-6 in biology and medicine. Adv Immunol 54: 1–78.
3. Borsellino N, Belldegrun A, Bonavida B . (1995). Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 55: 4633–4639.
4. Borsellino N, Bonavida B, Ciliberto G, Toniatti C, Travali S, D'Alessandro N . (1999). Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer 85: 134–144.
5. Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, Rivard N . (2000). MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 79: 355–369.
Cited by
94 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献